The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Congenital Heart Disease-Global Market Insights and Sales Trends 2025
Synopsis
The global Congenital Heart Disease market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Congenital Heart Disease in various end use industries. The expanding demands from the Hospitals and clinics and Diagnostic centres, are propelling Congenital Heart Disease market. Medication, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgical Therapy segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Congenital Heart Disease market, driven by demand from China, the second largest economy with some signs of stabilising, the Congenital Heart Disease market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Congenital Heart Disease, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Congenital Heart Disease market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Congenital Heart Disease market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Congenital Heart Disease sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Congenital Heart Disease covered in this report include Pfizer, Novartis, Abbott Laboratories, Roche, GSK, Sanofi, Johnson & Johnson, Medtronic and BD, etc.
The global Congenital Heart Disease market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Abbott Laboratories
Roche
GSK
Sanofi
Johnson & Johnson
Medtronic
BD
Boston Scientific
Merck
Eli Lilly
Mylan
Sun Pharmaceutical
AstraZeneca
Global Congenital Heart Disease market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Congenital Heart Disease market, Segment by Type:
Medication
Surgical Therapy
Global Congenital Heart Disease market, by Application
Hospitals and clinics
Diagnostic centres
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Congenital Heart Disease companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Congenital Heart Disease market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Congenital Heart Disease in various end use industries. The expanding demands from the Hospitals and clinics and Diagnostic centres, are propelling Congenital Heart Disease market. Medication, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgical Therapy segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Congenital Heart Disease market, driven by demand from China, the second largest economy with some signs of stabilising, the Congenital Heart Disease market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Congenital Heart Disease, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Congenital Heart Disease market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Congenital Heart Disease market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Congenital Heart Disease sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Congenital Heart Disease covered in this report include Pfizer, Novartis, Abbott Laboratories, Roche, GSK, Sanofi, Johnson & Johnson, Medtronic and BD, etc.
The global Congenital Heart Disease market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Abbott Laboratories
Roche
GSK
Sanofi
Johnson & Johnson
Medtronic
BD
Boston Scientific
Merck
Eli Lilly
Mylan
Sun Pharmaceutical
AstraZeneca
Global Congenital Heart Disease market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Congenital Heart Disease market, Segment by Type:
Medication
Surgical Therapy
Global Congenital Heart Disease market, by Application
Hospitals and clinics
Diagnostic centres
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Congenital Heart Disease companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Congenital Heart Disease
1.1 Congenital Heart Disease Market Overview
1.1.1 Congenital Heart Disease Product Scope
1.1.2 Congenital Heart Disease Market Status and Outlook
1.2 Global Congenital Heart Disease Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Congenital Heart Disease Market Size by Region (2018-2029)
1.4 Global Congenital Heart Disease Historic Market Size by Region (2018-2023)
1.5 Global Congenital Heart Disease Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Congenital Heart Disease Market Size (2018-2029)
1.6.1 North America Congenital Heart Disease Market Size (2018-2029)
1.6.2 Europe Congenital Heart Disease Market Size (2018-2029)
1.6.3 Asia-Pacific Congenital Heart Disease Market Size (2018-2029)
1.6.4 Latin America Congenital Heart Disease Market Size (2018-2029)
1.6.5 Middle East & Africa Congenital Heart Disease Market Size (2018-2029)
2 Congenital Heart Disease Market by Type
2.1 Introduction
2.1.1 Medication
2.1.2 Surgical Therapy
2.2 Global Congenital Heart Disease Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Congenital Heart Disease Historic Market Size by Type (2018-2023)
2.2.2 Global Congenital Heart Disease Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Congenital Heart Disease Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Congenital Heart Disease Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Congenital Heart Disease Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Congenital Heart Disease Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Congenital Heart Disease Revenue Breakdown by Type (2018-2029)
3 Congenital Heart Disease Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and clinics
3.1.2 Diagnostic centres
3.2 Global Congenital Heart Disease Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Congenital Heart Disease Historic Market Size by Application (2018-2023)
3.2.2 Global Congenital Heart Disease Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Congenital Heart Disease Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Congenital Heart Disease Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Congenital Heart Disease Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Congenital Heart Disease Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Congenital Heart Disease Revenue Breakdown by Application (2018-2029)
4 Congenital Heart Disease Competition Analysis by Players
4.1 Global Congenital Heart Disease Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Congenital Heart Disease as of 2022)
4.3 Date of Key Players Enter into Congenital Heart Disease Market
4.4 Global Top Players Congenital Heart Disease Headquarters and Area Served
4.5 Key Players Congenital Heart Disease Product Solution and Service
4.6 Competitive Status
4.6.1 Congenital Heart Disease Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Congenital Heart Disease Products, Services and Solutions
5.1.4 Pfizer Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Congenital Heart Disease Products, Services and Solutions
5.2.4 Novartis Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 Abbott Laboratories
5.3.1 Abbott Laboratories Profile
5.3.2 Abbott Laboratories Main Business
5.3.3 Abbott Laboratories Congenital Heart Disease Products, Services and Solutions
5.3.4 Abbott Laboratories Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.3.5 Roche Recent Developments
5.4 Roche
5.4.1 Roche Profile
5.4.2 Roche Main Business
5.4.3 Roche Congenital Heart Disease Products, Services and Solutions
5.4.4 Roche Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.4.5 Roche Recent Developments
5.5 GSK
5.5.1 GSK Profile
5.5.2 GSK Main Business
5.5.3 GSK Congenital Heart Disease Products, Services and Solutions
5.5.4 GSK Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.5.5 GSK Recent Developments
5.6 Sanofi
5.6.1 Sanofi Profile
5.6.2 Sanofi Main Business
5.6.3 Sanofi Congenital Heart Disease Products, Services and Solutions
5.6.4 Sanofi Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.6.5 Sanofi Recent Developments
5.7 Johnson & Johnson
5.7.1 Johnson & Johnson Profile
5.7.2 Johnson & Johnson Main Business
5.7.3 Johnson & Johnson Congenital Heart Disease Products, Services and Solutions
5.7.4 Johnson & Johnson Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.7.5 Johnson & Johnson Recent Developments
5.8 Medtronic
5.8.1 Medtronic Profile
5.8.2 Medtronic Main Business
5.8.3 Medtronic Congenital Heart Disease Products, Services and Solutions
5.8.4 Medtronic Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.8.5 Medtronic Recent Developments
5.9 BD
5.9.1 BD Profile
5.9.2 BD Main Business
5.9.3 BD Congenital Heart Disease Products, Services and Solutions
5.9.4 BD Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.9.5 BD Recent Developments
5.10 Boston Scientific
5.10.1 Boston Scientific Profile
5.10.2 Boston Scientific Main Business
5.10.3 Boston Scientific Congenital Heart Disease Products, Services and Solutions
5.10.4 Boston Scientific Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.10.5 Boston Scientific Recent Developments
5.11 Merck
5.11.1 Merck Profile
5.11.2 Merck Main Business
5.11.3 Merck Congenital Heart Disease Products, Services and Solutions
5.11.4 Merck Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.11.5 Merck Recent Developments
5.12 Eli Lilly
5.12.1 Eli Lilly Profile
5.12.2 Eli Lilly Main Business
5.12.3 Eli Lilly Congenital Heart Disease Products, Services and Solutions
5.12.4 Eli Lilly Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.12.5 Eli Lilly Recent Developments
5.13 Mylan
5.13.1 Mylan Profile
5.13.2 Mylan Main Business
5.13.3 Mylan Congenital Heart Disease Products, Services and Solutions
5.13.4 Mylan Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.13.5 Mylan Recent Developments
5.14 Sun Pharmaceutical
5.14.1 Sun Pharmaceutical Profile
5.14.2 Sun Pharmaceutical Main Business
5.14.3 Sun Pharmaceutical Congenital Heart Disease Products, Services and Solutions
5.14.4 Sun Pharmaceutical Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.14.5 Sun Pharmaceutical Recent Developments
5.15 AstraZeneca
5.15.1 AstraZeneca Profile
5.15.2 AstraZeneca Main Business
5.15.3 AstraZeneca Congenital Heart Disease Products, Services and Solutions
5.15.4 AstraZeneca Congenital Heart Disease Revenue (US$ Million) & (2018-2023)
5.15.5 AstraZeneca Recent Developments
6 North America
6.1 North America Congenital Heart Disease Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Congenital Heart Disease Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Congenital Heart Disease Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Congenital Heart Disease Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Congenital Heart Disease Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Congenital Heart Disease Market Dynamics
11.1 Congenital Heart Disease Industry Trends
11.2 Congenital Heart Disease Market Drivers
11.3 Congenital Heart Disease Market Challenges
11.4 Congenital Heart Disease Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
